Zenith Drugs Limited IPO
₹75 - ₹79
1600
179.18
| Open Date: | 19-Feb-2024 |
| Close Date: | 22-Feb-2024 |
| Allotment Date: | 23-Feb-2024 |
| Listing Date: | 27-Feb-2024 |
| Listing Price: | N/A |
| Face Value: | ₹10 Per Equity Share |
| Issue Price: | ₹75-79 Per Equity Share |
| Issue Size: | Total Issue Size 5,148,800 shares (aggregating up to ₹40.68 Cr) : Fresh Issue 5,148,800 shares (aggregating up to ₹40.68 Cr) |
| Market Lot (Min Amount): | Retail - ₹126,400 : HNI - ₹252,800 |
As on | QIB | Nll | Rll | Total |
|---|---|---|---|---|
| Shares Offered/Reserved | 859,200 | 644,800 | 1,504,000 | 3,008,000 |
| Day 1 - 19-02-24 05:00 PM | 0.00x | 0.99x | 3.42x | 1.92x |
| Day 2 - 20-02-24 05:00 PM | 3.53x | 2.50x | 9.41x | 6.25x |
| Day 3 - 21-02-24 05:00 PM | 3.54x | 7.98x | 19.42x | 12.43x |
| Day 4 - 22-02-24 05:00 PM | 106.72x | 368.77x | 139.28x | 179.18x |
| Total No. of Application: | 130,926 (Approx.) | |||
| Retail Subscription on the basis of Apps: | 139.28x | |||
| Earning Per Share(EPS) | ₹4.29/- |
| P/E Ratio | 18.4 |
| RoNW | 29.88% |
| Net Asset Value (NAV) - Post Issue: | ₹14.37/- |
| Total Assets | Total Revenue | Profit After Tax | |
|---|---|---|---|
| 31 Sep,2023 | 11,249.04 | 6,948.43 | 539.38 |
| 31 Mar,2023 | 9,793.83 | 11,569.65 | 515.29 |
| 31 Mar,2022 | 6,858.47 | 9,266.63 | 312.86 |
| Pre Issue Share Holding | 100% |
| Post Issue Share Holding | 69.98% |
| 1. Mr. Sandeep Bhardwaj |
| 2. Mr. Bhupesh Soni |
| 3. Mr. Ajay Singh Dassundi |
The Company intends to utilize the Net Fresh Issue Proceeds for the following Objects
- Purchase of Machinery & Equipments for Setting up New Unit
- Existing Manufacturing Block Upgradation
- Working Capital Requirements
- General Corporate Purposes.
Incorporated in 2000, Zenith Drugs Limited is a pharmaceutical company specialising in manufacturing and trading high-quality, affordable medicines, including generic drugs.
The company adheres to WHO-GMP guidelines and has received the ISO 9001:2015 certification from a respected EuroUK certification body, demonstrating its commitment to quality.
The product portfolio of the company includes
- ORS Powder;
- Liquid Orals;
- Ointments;
- Liquid Externals; and
- Capsules
The Food & Drugs Administration has approved over 600 products, of which 325 are currently in production.
The company is in the process of setting up a new manufacturing facility in Village Muradpura, Depalpur, Indore, Madhya Pradesh.
The company supplies its products to countries such as Costa Rica in Central America and the Caribbean and Pacific regions, Malawi, Mauritius, Mozambique, Sudan, Tanzania, Bhutan , Cambodia in Southeast Asia, Tajikistan, Liberia, Sierra Leone, and Conakry.
Zenith Drugs Limited specializes in third-party manufacturing, also known as white label manufacturing, for esteemed pharmaceutical companies such as Ajanta Pharma, Bio Medical Laboratories, and Zest Pharma, among others.
There are currently 89 employees as of March 31, 2023 - 61 on payroll and 28 on contract.
No financial information whatsoever published anywhere, within this application, should be considered as an advise to buy or sell securities or invest in IPOs, or as guide to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
Also we are not a SEBi registered analyst comapny. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this application. Above information is based on information available as on date coupled with market perceptions.
If you are agree with app tems and condition to use the app.
Thank you.